Ganser et al., 1986 - Google Patents
Treatment of AIDS-Related Kaposi's Sarcoma with Recombinant γ-InterferonGanser et al., 1986
- Document ID
- 8490869336732399251
- Author
- Ganser A
- Brücher W
- Brodt H
- Busch W
- Brandhorst I
- Helm E
- Hoelzer D
- Publication year
- Publication venue
- Oncology Research and Treatment
External Links
Snippet
Four patients with the acquired immunodeficiency syndrome and Kaposi's sarcoma were treated with subcutaneous human recombinant γ-interferon at a dosage of 200 μg 2× 106U twice daily for at least 28 days. While the dosage of interferon was well tolerated …
- 102000008070 Interferon-gamma 0 title abstract description 12
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/885—Immune response affecting drug
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/908—Leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/931—Veneral disease
- Y10S514/934—Virus
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69428992T2 (en) | IMMUNOLOGICAL IMPROVEMENT WITH INTERMITTENT INTERLEUKIN-2 THERAPY | |
| Storb et al. | Treatment of established human graft-versus-host disease by antithymocyte globulin | |
| EP0453898B1 (en) | Use of TNF-specific antibodies as a drug for treatment of ischemias and of their consequences | |
| MANNICK et al. | Prolongation of allograft survival by an alpha globulin isolated from normal blood | |
| Lane et al. | Use of interleukin-2 in patients with acquired immunodeficiency syndrome | |
| DE3328263C2 (en) | Aid for anti-tumor agents | |
| DE69434121T2 (en) | PHARMACEUTICAL COMPOSITION FOR IMMUNE-REINFORCING THERAPY | |
| Speed et al. | Melphalan in the treatment of myelomatosis | |
| Ganser et al. | Treatment of AIDS-Related Kaposi’s Sarcoma with Recombinant γ-Interferon | |
| Mirand et al. | Erythropoietin alterations in patients with uremia, renal allografts, or without kidneys | |
| Shepherd et al. | Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. | |
| DE68914653T2 (en) | INCREASE IN C1 INHIBITOR CONCENTRATIONS BY INTERFERON GAMMA ALONE OR IN COMBINATION WITH INTERLEUKIN-6. | |
| Ito et al. | Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma. Case reports | |
| DE69120396T2 (en) | NEW USE OF LINOMIDE (R) | |
| DE4138624C2 (en) | ||
| DE3786456T2 (en) | COMBINATIONS OF NECROSIS TUMOR FACTORS AND ANTI-INFLAMMATORY AGENTS FOR THE TREATMENT OF Vicious AND NON-Vicious DISEASES. | |
| KYLE et al. | Large doses of prednisone and prednisolone in the treatment of malignant lymphoproliferative disorders | |
| DE68907569T2 (en) | Aids for the treatment or prevention of AIDS. | |
| EP0500844B1 (en) | Drug containing cd14 | |
| Lipton et al. | Ocular masquerade syndrome in lymphoid blast crisis of chronic myeloid leukemia | |
| Steiner | Jaundice after transfusion of whole blood or human plasma | |
| DE69737088T2 (en) | THERAPEUTIC AGENT FOR THE TREATMENT OF FIV INFECTIONS | |
| DE3720434A1 (en) | METHOD FOR PRODUCING SPECIFIC IMMUNOMODULATORS FOR THE TREATMENT OF VIRUS-INDEX CAUSED BY VIRUSES AND MEDICINAL PRODUCT CONTAINING THE SAME | |
| DE69610045T2 (en) | Use of a raw plant extract for the manufacture of a medicament for the treatment of HIV infections | |
| Burchard et al. | Failure of high dose mebendazole as a microfilaricide in patients with loiasis |